ImmunoScience India Pvt. Ltd., and Biolinx Labsystems Pvt Ltd.’s collaborative efforts began by the development of ImmunoQuick® Covid-19 antibody test. It was developed on an urgent basis, starting in March. Their efforts have borne fruit and it has now been approved by the ICMR- National Institute of Virology and received registration from Central Drugs Standards Organisation (CDSCO) on April 16, 2020.
Unlike ordinary antibody tests, ImmunoQuick Covid-19 test separates the two forms of antibodies – IgM and IgG into separate bands. This has enormous advantages because clinicians can now separate patients into early infections, active patients and resolved/cured patients. “This is a game changer in the fight against Coronavirus in India” said Atul Tarde, company’s director of technology and operations.
Immunoscience is the brainchild of its founder, Dr. Sateesh Apte, who was born and was initially educated in Pune but who now lives in California. Biolinx Labsystems Pvt Ltd CEO Mr Mittal Gor who is an Engineer by training was instrumental in getting the product in its current shape. Mittal said, “We have the best scientific and business team anywhere in the world. They are innovative, knowledgeable and stand up to such challenging situation.
“Looking at the situation the entire world is currently in, helping clinicians with Rapid Screening of patients for Covid-19 infection is important. Hence it was critical to get this product urgently in the market. We standardised and optimised the efficiency until we achieved 100% accuracy”. said Dr Shrikant Pawar of Biolinx Labsystems. Dr Shrikant Pawar was a Scientist at NCMR, NCCS, Pune until February 2020. “The team has worked at breakneck speed, working night and day, sometimes from home, racing against time to bring this innovative product to market” said Mr Avinash Tulaskar, Consultant to Immunoscience. Mr. Amrut Kare.
Senior director of the various companies founded by Dr. Apte, including ImmunoScience gave invaluable support. Mr. Tarde said, “Every one of our tests conforms to the highest standards set forth by regulations and we are extremely proud of this. Our Covid-19 test will be no exception and will exceed all expectations. We want to be a major part of making India Covid-19 free.” “Biolinx Labsystems Pvt Ltd. has retained all the Distributorship rights as it has poured in all the investment required for getting the product to the market” said Mr. Mittal Gor. He also added that, “We are delighted to work with the ImmunoScience team to take this journey with them to help our fellow Indians. We have also kept the cost of the product to the minimum from Day 1 even though there is a huge demand and have received huge booking from all parts of the country”
Last news about this category